After its takeover was rejected last month by the U.S. biotech group’s board, the GlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to stakeholders. According to Hodson Stonex, currently the sixth largest investor in Human Genome, GSK made a good decision. But, still they will be facing payments for this. The […]
Continue Reading...
